Atara Biotherapeutics Inc (ATRA) concluded trading on Thursday at a closing price of $0.83, with 7.71 million shares of worth about $6.4 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -60.48% during that period and on Thursday, February 01 price saw a gain of about 33.10%. Currently the company’s common shares owned by public are about 129.19M shares, out of which, 117.42M shares are available for trading.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 45 times over the past 12 months. They bought 1,976,939 shares in 15 of the transactions. In 30 selling transactions, insiders dumped 251,889 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stock saw a price change of 37.62% in past 5 days and over the past one month there was a price change of 72.95%. Year-to-date (YTD), ATRA shares are showing a performance of 61.86% which decreased to -83.63% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.20 but also hit the highest price of $5.64 during that period. The average intraday trading volume for Atara Biotherapeutics Inc shares is 5.24 million. The stock is currently trading 38.28% above its 20-day simple moving average (SMA20), while that difference is up 38.29% for SMA50 and it goes to -44.52% lower than SMA200.
Atara Biotherapeutics Inc (NASDAQ: ATRA) currently have 129.19M outstanding shares and institutions hold larger chunk of about 69.69% of that.
The stock has a current market capitalization of $107.23M and its 3Y-monthly beta is at 0.64. It has posted earnings per share of -$2.77 in the same period. It has Quick Ratio of 1.42. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ATRA, volatility over the week remained 14.90% while standing at 13.22% over the month.
Analysts are in expectations that Atara Biotherapeutics Inc (ATRA) stock would likely to be making an EPS of $Kintara Therapeutics, Inc. in the current quarter, while forecast for next quarter EPS is $0.13 and it is $Stocks for next year. For the current quarter EPS, analysts have given the company a lowest target $Atara Biotherapeutics, Inc. which is $Natera, Inc. at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of $Athira Pharma, Inc. in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -9.15% while it is estimated to increase by 50.58% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Mizuho on November 09, 2023 offering a Neutral rating for the stock and assigned a target price range of between $31 and $1 to it.
